Enochian Biosciences Inc.

2.60-0.7300-21.92%Vol 1.11M1Y Perf -38.56%
Jun 27th, 2022 16:00 DELAYED
BID2.57 ASK2.63
Open3.37 Previous Close3.33
Pre-Market- After-Market2.60
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
-0.63 
Earnings Rating
Neutral
Market Cap137.67M 
Earnings Date
13th Jun 2022
Alpha0.04 Standard Deviation0.23
Beta0.44 

Today's Price Range

2.443.55

52W Range

2.6713.78

5 Year PE Ratio Range

-13.50-16.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.76%
1 Month
-10.00%
3 Months
-56.13%
6 Months
-58.27%
1 Year
-38.56%
3 Years
-32.04%
5 Years
52.05%
10 Years
-

TickerPriceChg.Chg.%
ENOB2.60-0.7300-21.92
AAPL141.660.00000.00
GOOG2 332.45-38.3100-1.62
MSFT264.89-2.8100-1.05
XOM89.032.13002.45
WFC40.24-0.5200-1.28
JNJ182.12-0.1700-0.09
FB196.640.99000.51
GE66.71-0.2900-0.43
JPM116.38-0.9400-0.80
Earnings HistoryEstimateReportedSurprise %
Q03 2022--0.12-
Q03 2020--0.03-
Q01 2020--0.09-
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1.11M
Shares Outstanding52.95K
Shares Float2.43M
Trades Count6.61K
Dollar Volume3.13M
Avg. Volume714.19K
Avg. Weekly Volume866.93K
Avg. Monthly Volume844.74K
Avg. Quarterly Volume430.91K

Enochian Biosciences Inc. (NASDAQ: ENOB) stock closed at 3.33 per share at the end of the most recent trading day (a 2.46% change compared to the prior day closing price) with a volume of 2.51M shares and market capitalization of 137.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Enochian Biosciences Inc. CEO is Mark R. Dybul.

The one-year performance of Enochian Biosciences Inc. stock is -38.56%, while year-to-date (YTD) performance is -54.32%. ENOB stock has a five-year performance of 52.05%. Its 52-week range is between 2.67 and 13.7799, which gives ENOB stock a 52-week price range ratio of -0.63%

Enochian Biosciences Inc. currently has a PE ratio of -4.20, a price-to-book (PB) ratio of 1.14, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -23.57%, a ROC of -23.78% and a ROE of -25.79%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Enochian Biosciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Enochian Biosciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Enochian Biosciences Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Enochian Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enochian Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enochian Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.26, ATR14 : 0.58, CCI20 : -47.36, Chaikin Money Flow : 0.10, MACD : -0.67, Money Flow Index : 56.68, ROC : -1.48, RSI : 38.27, STOCH (14,3) : 45.65, STOCH RSI : 1.00, UO : 33.78, Williams %R : -54.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enochian Biosciences Inc. in the last 12-months were: Carl Sandler (Sold 8 725 shares of value $78 861 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Enochian Biosciences Inc.

Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in identifying, developing, manufacturing, and commercializing gene therapies. The company develops cures and providing prevention for infectious diseases and cancer. It is also engaged in developing HIV preventative vaccine and cures and Cellular immune-oncology products.

CEO: Mark R. Dybul

Telephone: +1 786 888-1685

Address: 2080 Century Park East, Los Angeles 90067-2012, CA, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

60%40%

Bearish Bullish

53%47%

News

Stocktwits